RxDoctor Payments Data

Rachel Vanwormer

Family · West Branch, MINPI 1013366616

Payments from drug & device makers

$3,263in general payments, 2019–2025

Across 199 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$532
  • Lilly USA, LLC$371
  • AstraZeneca$354
  • Boehringer Ingelheim$307
  • AbbVie$275
  • Amgen$255
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,261100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,263 in reported general payments places this provider in the 85th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$146,500
RinvoqUpadacitinib17$132,486
JardianceEmpagliflozin85$109,464
MounjaroTirzepatide61$82,584
EliquisApixaban68$80,742
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$77,895
XareltoRivaroxaban52$55,810
FarxigaDapagliflozin Propanediol44$44,104
TrulicityDulaglutide36$42,389
VraylarCariprazine Hcl26$39,014
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr59$35,038
RybelsusSemaglutide16$28,079
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$25,346
InvokanaCanagliflozin16$25,062
JanuviaSitagliptin Phosphate19$19,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$532$174,579115 claims
AbbVieRinvoq, Vraylar$275$171,50043 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat, Spiriva Respimat$307$145,156133 claims
Lilly USA, LLCMounjaro, Trulicity$371$124,97297 claims
GSKTrelegy Ellipta, Anoro Ellipta$98$112,933126 claims
Johnson & JohnsonXarelto, Invokana$29$80,87268 claims
PfizerEliquis$227$80,74268 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere$354$79,85592 claims
MerckJanuvia, Dulera$32$25,50730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,657 family providers in Michigan.

Other family in West Branch

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →